{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:21Z","timestamp":1792021641403,"version":"4.4.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020180","name":"Japanese Society of Allergology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.alit.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:57:04Z","timestamp":1761364624000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical remission in severe asthma treated with biologics and macrolides: Definition, prevalence, associated factors, and future perspectives"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-652X","authenticated-orcid":false,"given":"Yuto","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2025.10.001_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","article-title":"Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy","volume":"72","author":"Nagase","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2025.10.001_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0238-2023","article-title":"Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials","volume":"33","author":"Kyriakopoulos","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.alit.2025.10.001_bib6","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/all.16178","article-title":"Real-world biologics response and super-response in the international severe asthma registry cohort","volume":"79","author":"Denton","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.10.001_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/resp.70047","article-title":"Unlocking asthma remission: key insights from an expert roundtable discussion","volume":"30","author":"Thomas","year":"2025","journal-title":"Respirology"},{"key":"10.1016\/j.alit.2025.10.001_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: a call for a globally standardised definition","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40487-021-00163-3","article-title":"What is the definition of cure in non-small cell lung cancer?","volume":"9","author":"Morgan","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.alit.2025.10.001_bib15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American college of allergy, asthma, and immunology, American academy of allergy, asthma, and immunology, and American thoracic society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib16","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1080\/02770903.2024.2376919","article-title":"SANI clinical remission definition: a useful tool in severe asthma management","volume":"61","author":"Canonica","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.alit.2025.10.001_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","article-title":"Spanish consensus on remission in asthma (REMAS)","volume":"60","author":"\u00c1lvarez-Guti\u00e9rrez","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.alit.2025.10.001_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.resinv.2025.03.009","article-title":"Practical guidelines for asthma management (PGAM): Digest edition","volume":"63","author":"Tamaoki","year":"2025","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2025.10.001_bib19","article-title":"GEMA 5.3. Spanish guideline on the management of asthma","volume":"5","author":"Plaza","year":"2023","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.alit.2025.10.001_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib22","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.1780241012","article-title":"Preliminary criteria for clinical remission in rheumatoid arthritis","volume":"24","author":"Pinals","year":"1981","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.alit.2025.10.001_bib23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with Benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.alit.2025.10.001_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","article-title":"Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial","volume":"166","author":"Thomas","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib27","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00782-2024","article-title":"Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma","volume":"65","author":"Hamada","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01497-2024","article-title":"Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma","volume":"65","author":"Soendergaard","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib32","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.resinv.2025.06.002","article-title":"Clinical and complete remission in patients with severe asthma with 24-month dupilumab treatment","volume":"63","author":"Tajiri","year":"2025","journal-title":"Respir Investig"},{"key":"10.1016\/j.alit.2025.10.001_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108203","article-title":"Clinical response and remission in patients treated with dupilumab for severe asthma: results from the nationwide Danish severe asthma register","volume":"245","author":"Hansen","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib35","article-title":"On-treatment clinical remission of severe asthma with real-world longer-term biologic use","volume":"4","author":"Chipps","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.alit.2025.10.001_bib36","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jaip.2025.03.011","article-title":"Concurrent blood eosinophils and FeNO as biological therapy indicators in severe asthma: findings from the precision medicine intervention in severe asthma study","volume":"13","author":"Pham","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/cea.70083","article-title":"Advancing remission in severe asthma with benralizumab: latest findings, current perspectives and future direction","volume":"55","author":"Louis","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107940","article-title":"The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: an ORBE II subanalysis","volume":"237","author":"Garc\u00eda-Moguel","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chest.2025.04.011","article-title":"XALOC-1: clinical remission over 2 years with benralizumab in severe eosinophilic asthma","volume":"168","author":"Pelaia","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib40","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","article-title":"Sputum type 2 markers could predict remission in severe asthma treated with Anti-IL-5","volume":"163","author":"Moermans","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaci.2024.03.023","article-title":"Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma","volume":"154","author":"Tang","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib43","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00117-2020","article-title":"Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena","volume":"56","author":"Mukherjee","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.10.001_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/all.16322","article-title":"Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: a feasibility study","volume":"80","author":"Mukherjee","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib48","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/thorax-2022-219781","article-title":"Super-responders to anti-IL-5\/anti-IL-5R are characterised by high sputum eosinophil counts at baseline","volume":"78","author":"Gerday","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2025.10.001_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108151","article-title":"High local type-2 inflammation is linked to response in severe asthma treated with anti-Interleukin-5 receptor","volume":"243","author":"Moermans","year":"2025","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.alit.2025.10.001_bib50","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2025.05.031","article-title":"Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma","volume":"156","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib51","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/ncomms3675","article-title":"Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation","volume":"4","author":"Kabata","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.alit.2025.10.001_bib52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaci.2017.03.032","article-title":"Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin","volume":"141","author":"Liu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.718267","article-title":"Immunobiology of steroid-unresponsive severe asthma","volume":"2","author":"Marshall","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201cSuper-Responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11096-021-01362-8","article-title":"Patient-reported outcome measures after 8 weeks of mepolizumab treatment and long-term outcomes in patients with severe asthma: an observational study","volume":"44","author":"Kroes","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.alit.2025.10.001_bib56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1183\/23120541.00559-2022","article-title":"Clinical response to benralizumab can be predicted by combining clinical outcomes at 3 months with baseline characteristics","volume":"9","author":"Kroes","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.alit.2025.10.001_bib57","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","article-title":"Benralizumab effectiveness in severe asthma is independent of previous biologic use","volume":"10","author":"Jackson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/all.16425","article-title":"Early reduction of FeNO on anti-IL5 biologics is associated with clinical remission of severe asthma","volume":"80","author":"Soendergaard","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib59","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/02770903.2024.2370012","article-title":"Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study","volume":"61","author":"Pianigiani","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.alit.2025.10.001_bib60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaip.2024.10.041","article-title":"Early treatment response to mepolizumab predicts clinical remission in severe eosinophilic asthma","volume":"13","author":"Hamada","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib61","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jaip.2025.05.002","article-title":"Treatable traits as a pathway to remission in asthma","volume":"13","author":"Farinha","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib62","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00861-2024","article-title":"Integrating hot topics and implementation of treatable traits in asthma","volume":"64","author":"Gibson","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib63","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits Down under international workshop report","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib65","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01509-2019","article-title":"Targeting treatable traits in severe asthma: a randomised controlled trial","volume":"55","author":"McDonald","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib66","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jaip.2022.05.012","article-title":"Effectiveness of interventions targeting treatable traits for the management of obstructive airway diseases: a systematic review and meta-analysis","volume":"10","author":"Sarwar","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib67","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jaip.2025.04.055","article-title":"Diagnosis and treatment options for T2-low asthma","volume":"13","author":"Thomas","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable traits in airway disease: from theory to practice","volume":"11","author":"Agusti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cea.12004","article-title":"Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial","volume":"43","author":"Scott","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.735030","article-title":"The management of extrapulmonary comorbidities and treatable traits; obesity, physical inactivity, anxiety, and depression, in adults with asthma","volume":"2","author":"McLoughlin","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib71","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaip.2024.01.020","article-title":"Treatable traits in asthma: the importance of extrapulmonary traits-GERD, CRSwNP, atopic dermatitis, and depression\/anxiety","volume":"12","author":"McDonald","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1164\/rccm.200510-1589OC","article-title":"Effects of smoking cessation on lung function and airway inflammation in smokers with asthma","volume":"174","author":"Chaudhuri","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib73","article-title":"Clinical remission of mild-to-moderate asthma: rates, contributing factors, and stability","volume":"4","author":"Ishizuka","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.alit.2025.10.001_bib74","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-017-0823-7","article-title":"Systematic meta-review of supported self-management for asthma: a healthcare perspective","volume":"15","author":"Pinnock","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.alit.2025.10.001_bib76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4104\/pcrj.2011.00025","article-title":"The importance of clinical management problems in older people with COPD and asthma: do patients and physicians agree?","volume":"20","author":"McDonald","year":"2011","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib77","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American college of rheumatology\/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.alit.2025.10.001_bib78","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","article-title":"No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [narrative review]","volume":"12","author":"Newsome","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.alit.2025.10.001_bib79","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.alit.2025.10.001_bib80","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jaip.2025.05.012","article-title":"\u201ctreat-to-target\u201d: a call for earlier targeted intervention in asthma","volume":"13","author":"Couillard","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib81","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaip.2025.05.019","article-title":"Disease modification in severe asthma-are we there yet?","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib82","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaip.2023.01.008","article-title":"Toward a predict and prevent approach in obstructive airway diseases","volume":"11","author":"Couillard","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib83","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1164\/rccm.202405-0894ED","article-title":"Remission in the world of severe asthma","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2023.06.015","article-title":"Impact of landscape fire smoke exposure on patients with asthma with or without laryngeal hypersensitivity","volume":"11","author":"Vertigan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib85","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/resp.70016","article-title":"Treatable trait guided asthma management: a feasibility study","volume":"30","author":"Fingleton","year":"2025","journal-title":"Respirology"},{"key":"10.1016\/j.alit.2025.10.001_bib86","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.anai.2025.03.013","article-title":"Worse airflow obstruction but not type 2 biomarkers identifies super-responders to tezepelumab in real life","volume":"134","author":"Greig","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib87","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blin, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"The Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib88","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/all.15901","article-title":"Effect of dupilumab on sputum eosinophils in patients with moderate-to-severe asthma","volume":"79","author":"Svenningsen","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib89","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib90","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib91","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib92","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.alit.2025.10.001_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(25)00174-2","article-title":"Eosinophils in asthma phenotypes: perpetrators or guilty by association?","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.10.001_bib94","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2025.10.001_bib95","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/all.16267","article-title":"Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma","volume":"79","author":"Fricker","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib96","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1111\/all.15909","article-title":"Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab","volume":"78","author":"Vultaggio","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib97","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaci.2024.11.024","article-title":"Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma","volume":"155","author":"Stewart","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib98","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2022.10.028","article-title":"Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma","volume":"151","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib99","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/all.16553","article-title":"Circulating mast cell progenitors are depleted by benralizumab in severe asthma","volume":"80","author":"Fricker","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2025.10.001_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2025.01.010","article-title":"Mucus plug score predicts clinical and pulmonary function response to biologic therapy in patients with severe asthma","volume":"13","author":"G\u00f6tschke","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib102","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.alit.2025.10.001_bib103","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","article-title":"Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blin, placebo-controlled trial","volume":"208","author":"Svenningsen","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib104","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT mucus score and 129Xe MRI ventilation defects after 2.5 years' anti-IL-5R\u03b1 in eosinophilic asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.chest.2025.02.004","article-title":"Does the reversal and normalization of airway and pulmonary vascular remodeling accompany asthma remission?","volume":"168","author":"Mozaffaripour","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.alit.2025.10.001_bib106","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blin, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2025.10.001_bib107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1164\/rccm.201809-1739OC","article-title":"Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma","volume":"200","author":"Taylor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.alit.2025.10.001_bib108","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/all.14768","article-title":"Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment","volume":"76","author":"Niessen","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib109","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/thoraxjnl-2020-216331","article-title":"Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy","volume":"76","author":"Shukla","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2025.10.001_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1449220","article-title":"Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience","volume":"15","author":"Stanziola","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.alit.2025.10.001_bib111","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-term clinical and sustained REMIssion in severe eosinophilic asthma treated with mepolizumab: the REMI-M study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/thorax-2024-222679","article-title":"Early clinical remission and its role in lung function decline and exacerbation in adult Korean patients with asthma","volume":"80","author":"Bae","year":"2025","journal-title":"Thorax"},{"key":"10.1016\/j.alit.2025.10.001_bib113","first-page":"309","article-title":"Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab","volume":"S1081\u20131206","author":"Hamada","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2022.04.005","article-title":"Can asthma biologics change the course of disease and induce drug-free remission?","volume":"150","author":"Cohn","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib115","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jaip.2025.05.031","article-title":"How to adjust asthma management once asthma is controlled on long-term biologic therapy","volume":"13","author":"Wechsler","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib116","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of discontinuing biologics in severe asthma: an algorithmic approach","volume":"14","author":"Hamada","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.alit.2025.10.001_bib117","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaip.2023.03.009","article-title":"Severe asthma standard-of-care background medication reduction with benralizumab: ANDHI in practice substudy","volume":"11","author":"Louis","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib118","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2025.10.001_bib119","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib120","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.04.031","article-title":"Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study","volume":"133","author":"Brightling","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2025.10.001_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.02.031","article-title":"Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics","volume":"9","author":"Jeffery","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.10.001_bib123","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00404-2024","article-title":"Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)","volume":"64","author":"Soendergaard","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.alit.2025.10.001_bib124","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK severe asthma registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025001145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025001145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:56:33Z","timestamp":1768460193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893025001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1323893025001145"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2025.10.001","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical remission in severe asthma treated with biologics and macrolides: Definition, prevalence, associated factors, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}